Vertex Pharmaceuticals Inc. buy tamam
Start price
21.09.15
/
50%
€104.92
Target price
21.03.16
€135.30
Performance (%)
-29.06%
End price
21.03.16
€74.43
Summary
This prediction ended on 21.03.16 with a price of €74.43. The price of Vertex Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -29.06%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 1.927% | 1.927% | 25.544% | 109.994% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% | 16.854% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% | 42.934% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% | 2.941% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% | 41.955% |
Comments by tamam for this prediction
In the thread Vertex Pharmaceuticals Inc. diskutieren
Buying on the pullback
Vertex boasts strong enough balance sheets and was upgraded to Overweight from Equal Weight by Barclays.
Financially, the company is sound: as of June 30, Vertex had $1.0
billion in cash after burning $130.7 million in Q2. Make no mistake,
with no competition on the horizon, ORKAMBI will achieve >90%
penetration as KALYDECO did. Current holders have no reason to sell, and
future investors will want to get on the boat to ride this pair of
guaranteed moneymakers sooner or later.
(Laufzeit überschritten)
Stopped prediction by tamam for Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€110.02
15.06.17
15.06.17
€270.00
04.11.21
04.11.21
52.01%
05.11.21
05.11.21
